Founded in 1996 by Walter Gilbert, Ph.D. and Stuart B. Levy, M.D., Paratek Pharmaceuticals is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering.

Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern.

Latest News

PRTK January 2016 Presentation (pdf)

Related News

9 Biotech Picks for 2016
Barron's
"It's the eve of a new year. So this seems like a great moment to look at the outlook for biotech stocks in 2016..."

Declaration of Support for Combating Antimicrobial Resistance